Electromagnetic Iontophoresis: A Novel Nonsurgical Method for the Treatment of Dense Vitreous and Retinal Hemorrhages.

IF 0.5 Q4 OPHTHALMOLOGY

Case Reports in Ophthalmology Pub Date : 2025-02-27 eCollection Date: 2025-01-01 DOI:10.1159/000544755

Umut Arslan, Deniz Arslan, Emin Özmert

{"title":"Electromagnetic Iontophoresis: A Novel Nonsurgical Method for the Treatment of Dense Vitreous and Retinal Hemorrhages.","authors":"Umut Arslan, Deniz Arslan, Emin Özmert","doi":"10.1159/000544755","DOIUrl":null,"url":null,"abstract":"Introduction: Vitreous, retinal, and suprochoroidal hemorrhages might develop secondary to trauma, retinal tear or detachment, neovascularization due to ischemic retina. If the clearance of retinal and vitreous hemorrhages can be accelerated, more effective treatments can be planned for the underlying pathology.Case presentations: We present 6 different cases with dense vitreous, preretinal, and subretinal hemorrhages due to Valsalva retinopathy, polypoid choroidal vasculopathy, diabetic retinopathy, neovascular age-related macular degeneration, retinitis pigmentosa with vasculitis, and myopic choroidal neovascularization. To accelerate the clearance of these dense intraocular hemorrhages, a novel nonsurgical method of electromagnetic iontophoresis (MagnoVision™) was used together with some appropriate medications in an outpatient setting without any complications or side effects. In all cases, liquefaction of the intraocular hemorrhage began by 5 days and mostly resolved by 10 days. This nonsurgical rapid clearance allowed us to diagnose and evaluate the underlying retinal and choroidal pathologies earlier and to treat them appropriately as early as possible.Conclusion: Combined use of electromagnetic iontophoresis, subtenon platelet-rich plasma and bevacizumab injection, and oral bromelain can be considered as an effective and safe new treatment method for vitreous and retinal hemorrhages without any need for surgical intervention.","PeriodicalId":9635,"journal":{"name":"Case Reports in Ophthalmology","volume":"16 1","pages":"221-231"},"PeriodicalIF":0.5000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11936436/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000544755","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Vitreous, retinal, and suprochoroidal hemorrhages might develop secondary to trauma, retinal tear or detachment, neovascularization due to ischemic retina. If the clearance of retinal and vitreous hemorrhages can be accelerated, more effective treatments can be planned for the underlying pathology.

Case presentations: We present 6 different cases with dense vitreous, preretinal, and subretinal hemorrhages due to Valsalva retinopathy, polypoid choroidal vasculopathy, diabetic retinopathy, neovascular age-related macular degeneration, retinitis pigmentosa with vasculitis, and myopic choroidal neovascularization. To accelerate the clearance of these dense intraocular hemorrhages, a novel nonsurgical method of electromagnetic iontophoresis (MagnoVision™) was used together with some appropriate medications in an outpatient setting without any complications or side effects. In all cases, liquefaction of the intraocular hemorrhage began by 5 days and mostly resolved by 10 days. This nonsurgical rapid clearance allowed us to diagnose and evaluate the underlying retinal and choroidal pathologies earlier and to treat them appropriately as early as possible.

Conclusion: Combined use of electromagnetic iontophoresis, subtenon platelet-rich plasma and bevacizumab injection, and oral bromelain can be considered as an effective and safe new treatment method for vitreous and retinal hemorrhages without any need for surgical intervention.

查看原文本刊更多论文

电磁离子导入：一种新的非手术治疗玻璃体和视网膜密集出血的方法。

玻璃体、视网膜和脉络膜上出血可继发于创伤、视网膜撕裂或脱离、视网膜缺血引起的新生血管。如果视网膜和玻璃体出血的清除可以加速，就可以为潜在的病理制定更有效的治疗方案。病例报告：我们报告了6例由Valsalva视网膜病变、息肉样脉络膜血管病变、糖尿病视网膜病变、新生血管性年龄相关性黄斑变性、视网膜色素变性伴脉络膜新生血管炎和近视引起的玻璃体、视网膜前和视网膜下致密出血。为了加速这些密集眼内出血的清除，一种新的非手术方法电磁离子导入（MagnoVision™）与一些适当的药物一起在门诊使用，没有任何并发症或副作用。在所有病例中，眼内出血液化开始于第5天，大部分在第10天消退。这种非手术快速清除使我们能够更早地诊断和评估潜在的视网膜和脉络膜病变，并尽可能早地进行适当的治疗。结论：电磁离子导入联合富血小板血浆与贝伐单抗注射液联合口服菠萝蛋白酶治疗玻璃体视网膜出血是一种有效、安全的治疗新方法，无需手术干预。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Case Reports in Ophthalmology OPHTHALMOLOGY-

CiteScore

0.90

自引率

0.00%

发文量

129

审稿时长

12 weeks

期刊介绍： This peer-reviewed online-only journal publishes original case reports covering the entire spectrum of ophthalmology, including prevention, diagnosis, treatment, toxicities of therapy, supportive care, quality-of-life, and survivorship issues. The submission of negative results is strongly encouraged. The journal will also accept case reports dealing with the use of novel technologies, both in the arena of diagnosis and treatment. Supplementary material is welcomed. The intent of the journal is to provide clinicians and researchers with a tool to disseminate their personal experiences to a wider public as well as to review interesting cases encountered by colleagues all over the world. Universally used terms can be searched across the entire growing collection of case reports, further facilitating the retrieval of specific information. Following the open access principle, the entire contents can be retrieved at no charge, guaranteeing easy access to this valuable source of anecdotal information at all times.